IN2012DN06589A - - Google Patents

Download PDF

Info

Publication number
IN2012DN06589A
IN2012DN06589A IN6589DEN2012A IN2012DN06589A IN 2012DN06589 A IN2012DN06589 A IN 2012DN06589A IN 6589DEN2012 A IN6589DEN2012 A IN 6589DEN2012A IN 2012DN06589 A IN2012DN06589 A IN 2012DN06589A
Authority
IN
India
Prior art keywords
mbl
sepsis
infectious diseases
provides
bind
Prior art date
Application number
Inventor
Michael Super
Jeffrey Charles Way
Donald E Ingber
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of IN2012DN06589A publication Critical patent/IN2012DN06589A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
    • G01N2333/39—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts
    • G01N2333/40—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts from Candida
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/72—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables
    • G01N27/74—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids
    • G01N27/745—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids for detecting magnetic beads used in biochemical assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Botany (AREA)

Abstract

The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases blood borne infections or sepsis. An aspect of the invention provides for mannose binding lectin (MBL) which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on virtually all classes of biopathogens (viruses bacteria fungi protozoans) make engineered forms of MBL extremely useful in diagnosing and treating infectious diseases and sepsis.
IN6589DEN2012 2010-01-19 2011-01-19 IN2012DN06589A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29622210P 2010-01-19 2010-01-19
PCT/US2011/021603 WO2011090954A2 (en) 2010-01-19 2011-01-19 Engineered opsonin for pathogen detection and treatment

Publications (1)

Publication Number Publication Date
IN2012DN06589A true IN2012DN06589A (en) 2015-10-23

Family

ID=44307537

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6589DEN2012 IN2012DN06589A (en) 2010-01-19 2011-01-19

Country Status (11)

Country Link
US (7) US9150631B2 (en)
EP (1) EP2526119B1 (en)
JP (5) JP5959440B2 (en)
CN (1) CN102947341B (en)
AU (1) AU2011207626B2 (en)
CA (1) CA2787376A1 (en)
DK (1) DK2526119T3 (en)
ES (1) ES2678143T3 (en)
IN (1) IN2012DN06589A (en)
SG (2) SG182577A1 (en)
WO (1) WO2011090954A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9220831B2 (en) 2005-10-06 2015-12-29 Children's Medical Center Corporation Device and method for combined microfluidic-micromagnetic separation of material in continuous flow
EP2347774B1 (en) 2005-12-13 2017-07-26 The President and Fellows of Harvard College Scaffolds for cell transplantation
WO2009102465A2 (en) 2008-02-13 2009-08-20 President And Fellows Of Harvard College Continuous cell programming devices
WO2010123594A2 (en) 2009-01-15 2010-10-28 Children's Medical Center Corporation Device for filtration of fluids there through and accompanying method
CA2787376A1 (en) 2010-01-19 2011-07-28 President And Fellows Of Harvard College Engineered opsonin for pathogen detection and treatment
EP2624873B1 (en) 2010-10-06 2019-12-04 President and Fellows of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
DE112012001444T5 (en) * 2011-03-25 2014-04-10 Receptors Llc Fiber having microbe removal or microbicidal power or ability to cause static growth
US20140220617A1 (en) * 2011-04-01 2014-08-07 Children's Medical Center Corporation Dialysis like therapeutic (dlt) device
SG10201608671SA (en) 2011-07-18 2016-12-29 Harvard College Engineered Microbe-Targeting Molecules and Uses Thereof
EP2820147B1 (en) * 2012-02-29 2018-08-08 President and Fellows of Harvard College Rapid antibiotic susceptibility testing
HUE047973T2 (en) 2012-04-16 2020-05-28 Harvard College Mesoporous silica compositions for modulating immune responses
US20130334120A1 (en) * 2012-06-15 2013-12-19 President And Fellows Of Harvard College Fluid cleansing devices and methods of use
EP2875078B1 (en) * 2012-07-18 2017-12-20 President and Fellows of Harvard College Modification of surfaces for simulataneous repellency and targeted binding of desired moieties
US10551379B2 (en) 2013-03-15 2020-02-04 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
AU2014268603B2 (en) 2013-05-21 2018-03-22 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
EP3748010A1 (en) 2013-07-15 2020-12-09 President and Fellows of Harvard College Assays for antimicrobial activity and applications thereof
EP3546474B1 (en) 2013-12-18 2021-07-07 President and Fellows of Harvard College Crp capture/detection of gram positive bacteria
DE102014206444A1 (en) * 2014-04-03 2015-10-08 Siemens Aktiengesellschaft A method for molecular diagnostics for enriching a nucleic acid from a biological sample
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
US10357780B2 (en) 2014-10-27 2019-07-23 President And Fellows Of Harvard College Magnetic capture of a target from a fluid
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
CN107708756A (en) 2015-04-10 2018-02-16 哈佛学院院长等 Immunocyte acquisition equipment and its preparation and application
US10435457B2 (en) 2015-08-06 2019-10-08 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
CA2997546A1 (en) 2015-09-14 2017-03-23 Medisieve Ltd Magnetic filter apparatus
CN115487351A (en) 2016-02-06 2022-12-20 哈佛学院校长同事会 Remodeling hematopoietic niches to reconstitute immunity
US10813988B2 (en) 2016-02-16 2020-10-27 President And Fellows Of Harvard College Pathogen vaccines and methods of producing and using the same
EP3458483A1 (en) 2016-05-16 2019-03-27 President and Fellows of Harvard College Aqueous biomolecule coupling on co2-plasma-activated surfaces
EP3484448A4 (en) 2016-07-13 2020-04-01 President and Fellows of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
US10639602B2 (en) 2016-07-28 2020-05-05 Medisieve Ltd Magnetic mixer and method
WO2019064463A1 (en) * 2017-09-28 2019-04-04 学校法人中部大学 Method and device for concentrating virus or bacterium using bioaffinity
KR102084688B1 (en) * 2018-06-18 2020-03-04 울산과학기술원 Method for detecting microorganisms using multiple probe hybridization
CN110628624B (en) * 2019-02-01 2022-07-15 传鸣(宁波)化学科技有限公司 Magnetic microorganism capturing material and microorganism capturing method
CN110294810B (en) * 2019-06-26 2021-05-04 中国疾病预防控制中心传染病预防控制所 Recombinant protein containing human IgG1Fc and mannan-binding lectin C-terminal
WO2021133943A1 (en) 2019-12-23 2021-07-01 Miraki Innovation Think Tank Llc Compositions, devices and methods for diagnosing and treating infectious disease
WO2021133963A1 (en) 2019-12-23 2021-07-01 Miraki Innovation Think Tank Llc Sample preparation and microbial analysis
CN111675825B (en) * 2020-06-09 2022-06-24 大连工业大学 Preparation method of microporous membrane attached with trypsin and application of microporous membrane in proteolysis
WO2021252902A1 (en) 2020-06-12 2021-12-16 Miraki Innovation Think Tank Llc Lateral flow assay for rapid detection of pathogens in samples
WO2022026800A2 (en) 2020-07-31 2022-02-03 Miraki Innovation Think Tank Llc Mbl-coated substrates having anti-thrombogenic properties
WO2022046558A1 (en) 2020-08-28 2022-03-03 Miraki Innovation Think Tank Llc Therapeutic compositions comprising microbe-targeting molecules and their use in methods of preventing and treating infectious disease
US20240019435A1 (en) 2020-09-25 2024-01-18 Miraki Innovation Think Tank Llc Compositions, devices and methods comprising microbe-targeting molecules for diagnosing and treating infectious disease
US20230416319A1 (en) 2020-10-01 2023-12-28 Miraki Innovation Think Tank Llc Compositions, devices and methods for identifying, treating and preventing infectious disease using microbe-targeting molecules
WO2022093935A1 (en) 2020-10-27 2022-05-05 Miraki Innovation Think Tank Llc Compositions, systems and methods for pathogen monitoring using microbe-targeting molecules
WO2022125632A1 (en) 2020-12-08 2022-06-16 Miraki Innovation Think Tank Llc Chimeric antigen receptor-expressing cells targeting microbe-associated molecular patterns
WO2022151333A1 (en) * 2021-01-15 2022-07-21 传鸣(宁波)化学科技有限公司 Mixture for enriching microorganisms, and method and application

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5418198A (en) 1977-07-09 1979-02-09 Toshimitsu Niwa Artificial intraretinal device
US4425330A (en) 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
JPS60500548A (en) 1982-12-03 1985-04-18 イ−・アイ・デユポン・ド・ネモア−ス・アンド・コンパニ− Chromogenic support immunoassay
EP0126772A1 (en) 1982-12-03 1984-12-05 E.I. Du Pont De Nemours And Company Chromogenic support immunoassay
JPH0718875B2 (en) 1987-06-19 1995-03-06 ヤマサ醤油株式会社 Method for measuring trace substance content in blood or body fluids
ATE165980T1 (en) 1987-08-20 1998-05-15 Childrens Medical Center NUCLIC ACID FRAGMENTS ENCODING MANNOSE BINDING FRAGMENTS FROM HUMAN MANNOSE BINDING PROTEIN
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
CA2008622A1 (en) 1989-01-25 1990-07-25 Kevin R. Gale Polypeptides antigens or vaccines protective against babesiosis
US5137810A (en) * 1989-04-26 1992-08-11 The University Of North Carolina Method of determining the gram sign of bacteria
DE4018583A1 (en) 1990-06-09 1991-12-12 Henkel Kgaa MODIFIED METHOD FOR THE DIRECT PRODUCTION OF ALKYL GLYCOSIDES
JP3322871B2 (en) 1990-07-30 2002-09-09 ノバルティス アクチエンゲゼルシャフト Insecticidal protein
GB9020075D0 (en) 1990-09-14 1990-10-24 Filler Aaron G Contrast agents for magnetic resonance imaging of axonal transport
JPH04130274A (en) 1990-09-20 1992-05-01 Kyoto Ikagaku Kenkyusho:Kk Method for analyzing and detecting sugar protein
US5783179A (en) 1991-08-09 1998-07-21 Syntex (U.S.A.) Inc. C-reactive protein fragment with immunomodulatory activity
US5405832A (en) 1991-11-27 1995-04-11 Immtech International Inc. Method of treating non-streptococcal bacterial infections
JP3457309B2 (en) 1991-11-27 2003-10-14 イムテック インターナショナル インコーポレイテッド How to treat viral infections
US5874238A (en) 1993-02-26 1999-02-23 Immtech International Inc. Mutant protein and methods and materials for making and using it
US5283238A (en) 1992-04-24 1994-02-01 Immtech International, Inc. Methods of treating cancer using modified C-reactive protein
US6703219B1 (en) 1993-02-26 2004-03-09 Immtech International Inc. Mutant protein and methods and materials for making and using it
IT1271486B (en) 1993-10-12 1997-05-28 Italfarmaco Spa IMMUNOMODULATORY OLIGOPEPTIDES DERIVED FROM FRAGMENTS OF C-REACTIVE PROTEIN
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
AUPN214095A0 (en) 1995-04-03 1995-04-27 Australian Water Technologies Pty Ltd Method for detecting microorganisms using flow cytometry
BR9708387A (en) 1996-03-28 2000-01-04 Genitrix Llc Process for vaccination of a mammal to a selected antigen, host and pathogenic cells, vaccine composition, nucleic acid, and engineered opsonin.
US6117977A (en) 1996-04-24 2000-09-12 Genentech, Inc. Type C lectins
ZA973051B (en) 1996-04-24 1998-10-12 Genentech Inc Type c lectins
FR2751229B1 (en) 1996-07-19 1998-11-27 Rhone Merieux POLYNUCLEOTIDE VACCINE FORMULA IN PARTICULAR AGAINST RESPIRATORY PATHOLOGY OF CATTLE
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
IL121191A0 (en) 1997-06-29 1997-11-20 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
JPH11206378A (en) 1998-01-23 1999-08-03 Fuso Pharmaceutical Industries Ltd Recombinant human mannan binding protein and its production
US7049099B2 (en) 1998-01-23 2006-05-23 Fuso Pharmaceutical Industries, Ltd. Recombinant human mannan-binding proteins and producing method of the same
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
JP4707231B2 (en) 1998-06-10 2011-06-22 スタテンズ セーラム インスティテュート Purification method and MBL pharmaceutical for producing mannan-binding lectin
WO2000006603A1 (en) 1998-07-31 2000-02-10 Asahi Kasei Kogyo Kabushiki Kaisha Antibody for detecting microorganism
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DK1181363T3 (en) 1999-05-14 2007-05-29 Thomas Vorup Jensen Recombinant human mannan-binding lectin
ES2317843T3 (en) 1999-07-13 2009-05-01 Bolder Biotechnology, Inc. FUSION PROTEINS OF ERYTHROPOYETIN-IMMUNOGLOBULIN.
US6503761B1 (en) 1999-10-19 2003-01-07 Kimberly-Clark Worldwide, Inc. Selective removal of contaminants from a surface using articles having magnets
JP5179689B2 (en) * 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Enhancing the half-life of antibody-based fusion proteins in the circulation
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
JP2002165591A (en) 2000-09-25 2002-06-11 Jsr Corp Magnetic particle and method for using the same
US20020146371A1 (en) 2000-10-18 2002-10-10 Li King Chuen Methods for development and use of diagnostic and therapeutic agents
GB0119274D0 (en) 2001-08-08 2001-10-03 Univ Durham Fusion proteins for insect control
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
AU2002359815A1 (en) * 2001-12-19 2003-07-09 Immunex Corporation C-type lectin polypeptide, polynucleotide and methods of making and use thereof
EP1335003A3 (en) 2002-02-06 2004-04-07 Toyo Boseki Kabushiki Kaisha Magnetic carrier capable of binding with protein and purification method of protein utilizing the magnetic carrier
JP4959110B2 (en) 2002-02-07 2012-06-20 マサチューセッツ インスティテュート オブ テクノロジー Anti-pathogen treatment
AU2003215524A1 (en) 2002-03-15 2003-09-29 Natimmune A/S Pharmaceutical compositions comprising mannose binding lectin
US20030180814A1 (en) 2002-03-21 2003-09-25 Alastair Hodges Direct immunosensor assay
US7211396B2 (en) 2002-04-18 2007-05-01 Antibodyshop A/S Antibody pairs and kits for immunochemical determination of mannan-binding lectin
NZ535600A (en) 2002-04-24 2008-03-28 Queensland Inst Med Res MASP-depleted MBL compositions are superior at activating the complement cascade when compared with MBL purified in complex with its associated MASPs
US20040018611A1 (en) 2002-07-23 2004-01-29 Ward Michael Dennis Microfluidic devices for high gradient magnetic separation
US7629440B2 (en) 2002-08-20 2009-12-08 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
AU2003265523A1 (en) * 2002-08-20 2004-03-11 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
EP1539964B1 (en) 2002-09-10 2006-12-27 Natlmmune A/S Collectin-complement activating protein chimeras
GB2393728A (en) 2002-10-04 2004-04-07 Nanomagnetics Ltd Magnetic nanoparticles
EP1417965A1 (en) 2002-11-07 2004-05-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs C-type lectin binding molecules, identification and uses thereof
CN101124315A (en) 2003-01-17 2008-02-13 伊势龙医学股份有限公司 Method for removal of viruses from blood by lectin affinity hemodialysis
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
DE10325752A1 (en) 2003-06-06 2004-12-30 Faustus Forschungs Cie. Translational Cancer Research Gmbh Lectin conjugates
EP1678197A4 (en) 2003-10-24 2008-05-07 Ludwig Inst Cancer Res Methods and compositions for pdgf-c activation and inhibition
KR20060124656A (en) * 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 Fc-erythropoietin fusion protein with improved pharmacokinetics
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
SE0401033D0 (en) 2004-04-20 2004-04-20 Amersham Biosciences Ab Device and method for protein analysis
WO2007001332A2 (en) 2004-08-04 2007-01-04 University Of Massachusetts Anti-pathogen immunoadhesins
WO2006018428A2 (en) 2004-08-20 2006-02-23 Novo Nordisk A/S Hemopexin fusion proteins
JP5255841B2 (en) 2004-10-15 2013-08-07 ジェネンコー・インターナショナル・インク Competitive differential screening
ES2360504T3 (en) 2004-10-28 2011-06-06 Dobeel Co., Ltd. METHOD FOR MASSED MULTIMERIC LECTIN MASS PRODUCTION.
US20060141547A1 (en) 2004-11-16 2006-06-29 Das Hasi R Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis
US7172906B2 (en) 2004-11-16 2007-02-06 Dade Behring Inc. Reduction of non-specific binding in assays
US8084275B2 (en) 2005-02-08 2011-12-27 Fujifilm Corporation Magnetic composite body, production method thereof, method for removing substance with mannose on its surface, and method for concentrating substance with mannose on its surface
AU2006232310B9 (en) * 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
WO2006108417A2 (en) 2005-04-11 2006-10-19 Natimmune A/S Mannan-binding lectin (mbl) in the treatment of immunocompromised conditions associated with cancer
US20070031819A1 (en) 2005-04-26 2007-02-08 University Of Washington Microfluidic systems for biological and molecular analysis and methods thereof
KR20140090270A (en) 2005-05-09 2014-07-16 바이오스피어 메디칼 에스.에이. Compositions and methods using microspheres and non-ionic contrast agents
US20070231833A1 (en) 2005-05-23 2007-10-04 Arcidiacono Steven M Labeled antimicrobial peptides and method of using the same to detect microorganisms of interest
JP4423394B2 (en) * 2005-06-17 2010-03-03 独立行政法人産業技術総合研究所 Novel sugar chain recognition protein and its gene
TWI333959B (en) 2005-08-31 2010-12-01 Academia Sinica Methods and reagents for the analysis and purification of polysaccharides
US20070184463A1 (en) 2005-09-30 2007-08-09 Caliper Life Sciences, Inc. Microfluidic device for purifying a biological component using magnetic beads
US9220831B2 (en) 2005-10-06 2015-12-29 Children's Medical Center Corporation Device and method for combined microfluidic-micromagnetic separation of material in continuous flow
US8013120B2 (en) 2005-10-26 2011-09-06 Stc.Unm C-reactive protein and its use to treat systemic lupus erythematosus and related conditions
US20070269818A1 (en) 2005-12-28 2007-11-22 Affymetrix, Inc. Carbohydrate arrays
US20090181041A1 (en) 2006-01-23 2009-07-16 Jan Holgersson Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
WO2008030631A2 (en) 2006-02-03 2008-03-13 Microchip Biotechnologies, Inc. Microfluidic devices
EP2005171B1 (en) 2006-03-23 2012-08-08 The General Hospital Corporation Inflammation-inhibitory serum factors and uses thereof
WO2007111496A1 (en) * 2006-03-28 2007-10-04 Universiteit Utrecht Holding B.V. Improved carbohydrate recognition domains
EP1862541A1 (en) 2006-06-01 2007-12-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides derived from the hemopexin-like domain of metalloproteinase MMP-2
US8273310B2 (en) 2006-09-05 2012-09-25 Samsung Electronics Co., Ltd. Centrifugal force-based microfluidic device for nucleic acid extraction and microfluidic system including the microfluidic device
KR101343034B1 (en) 2006-09-05 2013-12-18 삼성전자 주식회사 Centrifugal microfluidic device for target protein detection and microfluidic system comprising the same
US8088596B2 (en) * 2006-10-10 2012-01-03 Oakland University Method of microorganism detection using carbohydrate and lectin recognition
US8551333B2 (en) 2007-04-05 2013-10-08 The Regents Of The University Of California Particle-based microfluidic device for providing high magnetic field gradients
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
WO2008130618A1 (en) 2007-04-19 2008-10-30 The Charles Stark Draper Laboratory, Inc. Method and apparatus for separating particles, cells, molecules and particulates
US20090252729A1 (en) 2007-05-14 2009-10-08 Farrington Graham K Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto
EP2162472B1 (en) 2007-05-30 2013-02-27 Postech Academy-Industry- Foundation Immunoglobulin fusion proteins
WO2009039973A2 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of peptide arg-asn-ile-ala-glu-ile-ile-lys-asp-ile-oh or its combination with the peptide asp-arg-gly-asp-ser-oh as a therapeutic agent
CN102066415A (en) 2007-10-29 2011-05-18 弗吉尼亚科技知识产权有限公司 Porcine DC-SIGN, ICAM-3 and LSECtin and uses thereof
WO2009062195A2 (en) 2007-11-09 2009-05-14 Anaphore, Inc. Fusion proteins of mannose binding lectins for treatment of disease
ES2326109B1 (en) 2007-12-05 2010-06-25 Consejo Superior De Investigaciones Cientificas SELECTIVE AND NON INVASIVE SEPARATION AND EXTRACTION MICRODISPOSITIVE OF PARTICLES IN POLIDISPERSE SUSPENSIONS, MANUFACTURING PROCEDURE AND ITS APPLICATIONS.
US20100266558A1 (en) 2007-12-18 2010-10-21 Dov Zipori Method and assay for glycosylation pattern detection related to cell state of stem cells
US20110183398A1 (en) 2007-12-31 2011-07-28 3M Innovative Properties Microorganism-capturing compositions and methods
WO2009126346A2 (en) 2008-01-18 2009-10-15 The General Hospital Corporation Methods for prevention and treatment of infections with supraphysiological doses of mannan-binding lectin (mbl) and ficolin-mbl fusion proteins
CN101990575B (en) 2008-03-28 2015-06-17 国立大学法人北海道大学 Anti-(influenza a virus subtype h5 hemagglutinin) monoclonal antibody
EP2267151A4 (en) 2008-03-31 2011-06-29 Japan Tobacco Inc Virus titration method
US20110053250A1 (en) 2008-03-31 2011-03-03 Japan Tobacco Inc. Enrichment method of virus
US20100323429A1 (en) 2008-04-10 2010-12-23 Yu-Chen Hu Methods for purifying baculovirus
US8865876B2 (en) 2008-06-02 2014-10-21 California Institute Of Technology Engineered lectin oligomers with antiviral activity
BRPI0909910A2 (en) 2008-06-03 2016-10-11 Stc Unm "method of treating, inhibiting or reducing the likelihood of systemic lupus erythematosus (les) or of a secondary disease state, condition or manifestation associated with systemic lupus erythematosus or immune thrombocytopenic purpura in a patient, pharmaceutical composition and its use"
JP2010122205A (en) 2008-08-29 2010-06-03 Sysmex Corp Method for detecting measles virus, membrane assay test device, and membrane assay test kit
US20110159000A1 (en) 2008-09-05 2011-06-30 The Regents Of The University Of California Antibodies with mannose binding lectin effector function for inhibiting pathologic inflammatory conditions
WO2010065765A2 (en) 2008-12-04 2010-06-10 Aethlon Medical, Inc. Affinity capture of circulating biomarkers
CA2748015C (en) 2008-12-22 2017-02-28 National University Corporation Hokkaido University Protein substance having triple helix structure and manufacturing method therefor
US8664366B2 (en) * 2009-01-09 2014-03-04 Apogenix Gmbh Fusion proteins forming trimers
AU2010206681A1 (en) 2009-01-23 2011-09-01 Biogen Idec Ma Inc. Stabilized Fc polypeptides with reduced effector function and methods of use
US20110281792A1 (en) 2009-01-28 2011-11-17 Zion Todd C Binding-site modified lectins and uses thereof
US20130012451A1 (en) 2009-12-21 2013-01-10 The Research Foundation Of State University Of New York Compositions and methods for inhibiting mmp-9-mediated cell migration
CA2787376A1 (en) 2010-01-19 2011-07-28 President And Fellows Of Harvard College Engineered opsonin for pathogen detection and treatment
WO2011091037A2 (en) 2010-01-19 2011-07-28 President And Fellows Of Harvard College Rapid pathogen diagnostic device and method
CA2825008C (en) 2011-01-19 2020-10-13 President And Fellows Of Harvard College Slippery surfaces with high pressure stability, optical transparency, and self-healing characteristics
US20140220617A1 (en) 2011-04-01 2014-08-07 Children's Medical Center Corporation Dialysis like therapeutic (dlt) device
SG10201608671SA (en) 2011-07-18 2016-12-29 Harvard College Engineered Microbe-Targeting Molecules and Uses Thereof

Also Published As

Publication number Publication date
US20200095300A1 (en) 2020-03-26
JP6960957B2 (en) 2021-11-05
AU2011207626A2 (en) 2012-10-04
JP6513604B2 (en) 2019-05-15
EP2526119A4 (en) 2013-10-02
EP2526119A2 (en) 2012-11-28
US20130035283A1 (en) 2013-02-07
CN102947341B (en) 2018-07-06
US20220056089A1 (en) 2022-02-24
WO2011090954A3 (en) 2012-01-12
CN102947341A (en) 2013-02-27
SG182577A1 (en) 2012-08-30
JP2022097536A (en) 2022-06-30
JP2019142901A (en) 2019-08-29
US20200291083A1 (en) 2020-09-17
JP2017014194A (en) 2017-01-19
US11203623B2 (en) 2021-12-21
US11059873B2 (en) 2021-07-13
JP2013517327A (en) 2013-05-16
US20200299345A1 (en) 2020-09-24
JP7062723B2 (en) 2022-05-06
US20160200785A1 (en) 2016-07-14
WO2011090954A2 (en) 2011-07-28
JP5959440B2 (en) 2016-08-02
EP2526119B1 (en) 2018-05-30
US11059874B2 (en) 2021-07-13
US10538562B2 (en) 2020-01-21
US9150631B2 (en) 2015-10-06
JP2020193201A (en) 2020-12-03
AU2011207626B2 (en) 2015-06-18
AU2011207626A1 (en) 2012-08-09
CA2787376A1 (en) 2011-07-28
SG10201503351RA (en) 2015-06-29
DK2526119T3 (en) 2018-07-30
ES2678143T3 (en) 2018-08-09
US20180094035A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
IN2012DN06589A (en)
Horowitz Fever of unknown origin or fever of too many origins?
CY1124488T1 (en) PROTEIN RELEASE BASED ON INFECTIOUSNESS-ATTAINED BACTERIA
MY183517A (en) Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
PH12014501776A1 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
EA201000424A1 (en) ANTIBODIES TO IL-23
BR112014023005A2 (en) quick diagnosis and personalized acne treatments
AU2012249274A8 (en) Neutralizing antibodies to Nipah and Hendra virus
EA201001212A8 (en) TREATMENT OF MICROBIAL INFECTIONS
CO6630164A2 (en) Proteins that bind to tnf-a
IL187321A (en) Host cell specific binding molecules encoding monoclonal antibodies capable of neutralizing viruses, pharmaceutical compositions comprising them and uses thereof in the preparation of medicaments
EP3912986A3 (en) Crp capture/detection of bacteria
EA201491481A1 (en) Allergen timofeed meadow and methods and applications for modulating immune response
BR112017004059A2 (en) usable hemoperfusion device
ATE503769T1 (en) ANTIBODIES AGAINST HUMAN CYTOMEGALY VIRUS (HCMV)
MX2011004483A (en) Leukolectins and uses thereof.
BR112014023642A2 (en) interferon-lambda4 (ifnl4) protein, related antibody molecules, and uses thereof
BR112019007147A2 (en) anti-o1 antibodies and uses thereof
CY1116962T1 (en) HUMAN WHEELS AND THEIR USES
BR112019002039A2 (en) anti-o2 antibodies and their use
BR112014023063A2 (en) antibodies that neutralize rsv, mpv and pvm and their uses
Al-Otair et al. Venous thromboembolism in a medical intensive care unit. The effect of implementing clinical practice guidelines
BR112018003252A2 (en) mrka polypeptides, antibodies, and uses thereof
WO2012119989A3 (en) Antibodies against cadmi for the diagnosis and treatment of cancer
UA64465U (en) Method for diagnostics of dysplasia of connective tissue in patients with tuberculosis of respiratory system